MG-BAC

Indications

• Bacterial infections in poultry
• Respiratory infections
• Enteritis
• Bacterial pneumonia

Dosage

Children: Refer to veterinary guidelines for appropriate dosing based on the infection being treated and the animal's weight.

Adults: Refer to veterinary guidelines for appropriate dosing based on the infection being treated and the animal's weight.

Mechanism of action

Gallisepticum works by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. This action prevents the translocation of peptides and halts the growth of bacteria, making it bacteriostatic. Its selectivity for bacterial ribosomes over mammalian ribosomes contributes to its therapeutic efficacy and safety profile.

Pharmacodynamics

The pharmacodynamic profile of gallisepticum indicates that it is effective at low concentrations against susceptible microorganisms. The drug exhibits a time-dependent killing effect, meaning that the duration of exposure at therapeutic levels is critical for achieving optimal antibacterial activity. Resistance may develop through various mechanisms, including methylation of adenine residues in the 23S rRNA, which decreases drug binding.

Pharmacokinetics

Gallisepticum is well absorbed from the gastrointestinal tract when administered orally. It undergoes extensive metabolism in the liver, with a significant first-pass effect. The elimination half-life varies depending on the species but generally ranges from several hours to a day. The drug is primarily excreted through bile and urine, with a minor fraction excreted unchanged. Its distribution in tissues is wide, allowing effective penetration into respiratory tissues.

Pregnancy

There is limited data on the use of gallisepticum during pregnancy. It is advisable to use caution and consult with a healthcare provider.

Breast-feeding

There is insufficient information regarding the excretion of gallisepticum in human milk. Caution is recommended if administered during breastfeeding.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Mycoplasma pneumonia
• Atypical pneumonia
• Respiratory tract infections
• Sinusitis
• Bronchitis
• Chronic cough

Dosage

Children: Refer to specific antibiotic guidelines as the dosage depends on the antibiotic chosen for treatment

Adults: Refer to specific antibiotic guidelines as the dosage depends on the antibiotic chosen for treatment.

Mechanism of action

Mycoplasma species, particularly Mycoplasma pneumoniae, adhere to the respiratory epithelial cells and disrupt normal cellular processes. They utilize surface proteins and lipids to anchor themselves to host cells, leading to cell damage through inflammatory responses. They do not produce toxins but can induce host immune responses that contribute to the pathogenicity of the infection.

Pharmacodynamics

Mycoplasma are unique bacteria that lack a cell wall, which makes them resistant to many common antibiotics, such as penicillins and cephalosporins. The treatment of infections caused by Mycoplasma typically involves the use of antibiotics that target protein synthesis, such as macrolides (e.g., azithromycin) or tetracyclines (e.g., doxycycline). These antibiotics inhibit bacterial growth by disrupting essential processes within the bacteria, leading to cell death or stasis.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat Mycoplasma infections can vary. For example, macrolides are well-absorbed orally and have good tissue penetration, allowing them to reach the site of infection effectively. They are metabolized in the liver and excreted primarily through bile. Tetracyclines also have good oral bioavailability and are distributed widely in body tissues, but should be avoided in children under 8 years due to potential effects on bone and tooth development. The half-lives of these antibiotics can range from several hours to a day, depending on the specific drug and patient factors.

Pregnancy

Mycoplasma infections should be treated with caution during pregnancy. The use of antibiotics may be necessary, but the choice of medication should consider safety profiles and potential risks to the fetus.

Breast-feeding

Caution is advised when treating Mycoplasma infections in breastfeeding individuals. Certain antibiotics may be excreted in breast milk, so a risk-benefit assessment is essential.

Storage

Store in a cool, dry place away from direct sunlight. Specific conditions may vary depending on the antibiotic used for treatment.